These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 4422149)

  • 1. Dopamine 3-O-sulphate, an end product of L-dopa metabolism in Parkinson patients.
    Jenner WN; Rose FA
    Nature; 1974 Nov; 252(5480):237-8. PubMed ID: 4422149
    [No Abstract]   [Full Text] [Related]  

  • 2. Conjugation of L-DOPA and its metabolites after oral and intravenous administration to Parkinsonian patients.
    Bronaugh RL; MacMurtry RJ; Hoehn MM; Rutledge CO
    Biochem Pharmacol; 1975 Jul; 24(13-14):1317-20. PubMed ID: 1096899
    [No Abstract]   [Full Text] [Related]  

  • 3. The separation and identification of dopamine 3-O-sulfate and dopamine 4-O-sulfate in urine of Parkinsonian patients.
    Bronaugh RL; Hattox SE; Hoehn MM; Murphy RC; Rutledge CO
    J Pharmacol Exp Ther; 1975 Dec; 195(3):441-52. PubMed ID: 1195131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
    Maruyama W; Naoi M; Narabayashi H
    J Neurol Sci; 1996 Jul; 139(1):141-8. PubMed ID: 8836986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose.
    Granerus AK; Jagenburg R; Rödjer S; Svanborg A
    Acta Med Scand; 1974 Dec; 196(6):459-63. PubMed ID: 4456974
    [No Abstract]   [Full Text] [Related]  

  • 6. High-performance liquid chromatographic determination of dopamine sulfoconjugates in urine after L-dopa administration.
    Arakawa Y; Imai K; Tamura Z
    J Chromatogr; 1979 Mar; 162(3):311-8. PubMed ID: 528597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulphate conjugation and L-dopa treatment of Parkinsonian patients.
    Rutledge CO; Hoehn MM
    Nature; 1973 Aug; 244(5416):447-50. PubMed ID: 4582501
    [No Abstract]   [Full Text] [Related]  

  • 8. Parkinson's disease: the effect of L-dopa therapy on urinary free catecholamines and metabolites.
    Davidson DF; Grosset K; Grosset D
    Ann Clin Biochem; 2007 Jul; 44(Pt 4):364-8. PubMed ID: 17594783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term l-DOPA therapy for parkinsonism and its pathochemical aspect].
    Petelin LS; Vartanian KZ; Romenskaia LKh
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1977; 77(12):1810-3. PubMed ID: 602554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma detection by enzyme-radioimmunoassay of L-dopa, dopamine, and 3-O-methyldopamine in urine.
    Faraj BA; Lawson DH; Nixon DW; Murray DR; Camp VM; Ali FM; Black M; Stacciarini W; Tarcan Y
    Clin Chem; 1981 Jan; 27(1):108-12. PubMed ID: 7004664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 3-OM-dopa on monoamine metabolism in rat brain.
    Gervas JJ; Muradás V; Bazán E; Aguado EG; de Yébenes JG
    Neurology; 1983 Mar; 33(3):278-82. PubMed ID: 6681870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxic effects of dopamine metabolism in Parkinson's disease.
    Hattoria N; Wanga M; Taka H; Fujimura T; Yoritaka A; Kubo S; Mochizuki H
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S35-8. PubMed ID: 19131041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation.
    Spencer SE; Wooten GF
    Neurology; 1984 Aug; 34(8):1105-8. PubMed ID: 6540390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
    Kostrzewa RM; Kostrzewa JP; Brus R
    Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa for the treatment of Parkinson's disease.
    Lewitt PA
    N Engl J Med; 2008 Dec; 359(23):2468-76. PubMed ID: 19052127
    [No Abstract]   [Full Text] [Related]  

  • 16. The formation of 3-hydroxy-4-methoxyphenylalanine and 3-hydroxy-4-methoxyphenethylamine in plasma during L-DOPA therapy in patients with Parkinson's disease.
    Ishimitsu T; Hirose S; Asahara K; Imaizumi M
    Chem Pharm Bull (Tokyo); 1984 Aug; 32(8):3320-2. PubMed ID: 6518609
    [No Abstract]   [Full Text] [Related]  

  • 17. Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.
    Blandini F; Nappi G; Fancellu R; Mangiagalli A; Samuele A; Riboldazzi G; Calandrella D; Pacchetti C; Bono G; Martignoni E
    J Neural Transm (Vienna); 2003 Aug; 110(8):911-22. PubMed ID: 12898346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-dopa in Parkinson's disease.
    Horstink MW; van de Vlasakker CJ
    Neurology; 1991 Oct; 41(10):1709. PubMed ID: 1922837
    [No Abstract]   [Full Text] [Related]  

  • 19. [Contribution to the biochemical treatment of the Parkinson's disease (author's transl)].
    Calatayud Maldonado V
    Rev Esp Otoneurooftalmol Neurocir; 1978; 36(204):33-41. PubMed ID: 741072
    [No Abstract]   [Full Text] [Related]  

  • 20. Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease.
    Nakazato T; Akiyama A
    Brain Res; 2002 Mar; 930(1-2):134-42. PubMed ID: 11879803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.